Paolo Tarantino: We desperately need a biomarker to refine treatment for early-stage TNBC

Paolo Tarantino shared a post on X about a recent paper by M. Martín et al. published in Annals of Oncology.

“Interesting validation analysis of TNBC-DX in over 500 patients with TNBC treated with neoadjuvant chemo+/-pembro. The multigene assay significantly predicted pCR, DDFS/EFS and OS.

We desperately need a biomarker to refine treatment for early-stage TNBC.”

“TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy”

Authors: M. Martín, S.R. Stecklein, O. Gluz, A. Prat, P. Sharma, N. Harbeck et al.

More posts featuring Paolo Tarantino.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.